114 related articles for article (PubMed ID: 3524832)
1. Simple method for the administration of high-dose etoposide during autologous bone marrow transplantation.
Lazarus HM; Creger RJ; Diaz D
Cancer Treat Rep; 1986 Jun; 70(6):819-20. PubMed ID: 3524832
[No Abstract] [Full Text] [Related]
2. High-dose etoposide with autologous bone marrow transplantation as initial treatment of small cell lung cancer--a negative report.
Littlewood TJ; Bentley DP; Smith AP
Eur J Respir Dis; 1986 May; 68(5):370-4. PubMed ID: 3015650
[TBL] [Abstract][Full Text] [Related]
3. [A phase II trial of etoposide (VP-16) administered intravenously in the treatment of malignant lymphoma and acute leukemia].
Moriyama Y; Shibata A; Maekawa I; Yoshida Y; Miura A; Wakui A; Kariyone S; Maekawa T; Miura Y; Abe T
Rinsho Ketsueki; 1985 Nov; 26(11):1774-84. PubMed ID: 3835288
[No Abstract] [Full Text] [Related]
4. Feasibility of high dose VP 16-213 as single agent or in combination with cyclophosphamide and autologous bone marrow transplantation (ABMT).
Mulder NH; Meinesz AF; Sleijfer DT; Postmus PE; De Vries EG; Van der Geest S; Orie JL; Vriesendorp R
Neth J Med; 1984; 27(10):389-92. PubMed ID: 6096742
[No Abstract] [Full Text] [Related]
5. When is autologous bone marrow transplantation safe after high-dose treatment with etoposide?
Littlewood TJ; Spragg BP; Bentley DP
Clin Lab Haematol; 1985; 7(3):213-8. PubMed ID: 3907938
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of etoposide in advanced prostate cancer.
Trump DL; Loprinzi CL
Cancer Treat Rep; 1984 Sep; 68(9):1195-6. PubMed ID: 6478456
[No Abstract] [Full Text] [Related]
7. [Phase II study of etoposide (NK 171) in advanced hematological malignancies].
Yoshida T; Nakanishi J; Ito K; Kobayashi S; Ohtake S; Nakamura S; Hattori K
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835
[TBL] [Abstract][Full Text] [Related]
8. Etoposide--an effective single drug for treating bronchogenic carcinoma.
Anderson G; Peel ET; Cheong CM; Broderick NJ
Clin Oncol; 1982; 8(3):215-8. PubMed ID: 7140048
[No Abstract] [Full Text] [Related]
9. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA
Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323
[TBL] [Abstract][Full Text] [Related]
10. Etoposide infusions for treatment of metastatic lung cancer.
Steward WP; Thatcher N; Edmundson JM; Shiu W; Wilkinson PM
Cancer Treat Rep; 1984 Jun; 68(6):897-9. PubMed ID: 6329509
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer.
Bertrand M; Multhauf P; Presant C; Rappaport D; Blayney DW; Carr BI; Cecchi G; Doroshow JH; Emont E; Goldberg D
Cancer Treat Rep; 1985 Nov; 69(11):1335-6. PubMed ID: 4092199
[No Abstract] [Full Text] [Related]
12. [Effect of etoposide for pulmonary metastases from urogenital tract cancer].
Fujita K; Murayama T; Sayama T
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2438-41. PubMed ID: 6497402
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
Lokich J; Corkery J
Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
[TBL] [Abstract][Full Text] [Related]
14. Etoposide (VP-16-213). Current status of an active anticancer drug.
O'Dwyer PJ; Leyland-Jones B; Alonso MT; Marsoni S; Wittes RE
N Engl J Med; 1985 Mar; 312(11):692-700. PubMed ID: 2983208
[No Abstract] [Full Text] [Related]
15. High-dose etoposide for refractory malignancies: a phase I study.
Postmus PE; Mulder NH; Sleijfer DT; Meinesz AF; Vriesendorp R; de Vries EG
Cancer Treat Rep; 1984 Dec; 68(12):1471-4. PubMed ID: 6509453
[TBL] [Abstract][Full Text] [Related]
16. [Phase I study of an oral administration of VP 16-213].
Ogawa M; Ota K; Oyama A; Fukuoka M; Takada M; Yoshida S; Sanpi K; Kimura I; Ohnoshi T; Kuraishi Y
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2403-7. PubMed ID: 6639102
[TBL] [Abstract][Full Text] [Related]
17. Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation.
Ciobanu N; Paietta E; Andreeff M; Papenhausen P; Wiernik PH
Exp Hematol; 1986 Aug; 14(7):626-35. PubMed ID: 3525202
[TBL] [Abstract][Full Text] [Related]
18. High-dose etoposide as single-agent chemotherapy for small cell carcinoma of the lung.
Wolff SN; Johnson DH; Hande KR; Hainsworth JD; Greco FA
Cancer Treat Rep; 1983 Oct; 67(10):957-8. PubMed ID: 6313189
[No Abstract] [Full Text] [Related]
19. Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.
Vaughn CB; Panettiere F; Thigpen T; Bottomley R; Hoogstraten B; Samal B
Cancer Treat Rep; 1981; 65(5-6):443-5. PubMed ID: 7237465
[No Abstract] [Full Text] [Related]
20. Lack of severe hypotension with VP-16-213 administered directly lv.
Cavalli F; Sonntag RW; Ryssel HJ; Brunner KW
Cancer Treat Rep; 1977 Oct; 61(7):1411. PubMed ID: 589604
[No Abstract] [Full Text] [Related]
[Next] [New Search]
